3HY Stock Overview
Arix Bioscience plc is a venture capital firm specializing in all stages of growth, seed stage, preclinical and clinical stage assets, startup, early stage, mid venture, late stage, growth capital investments as well as private and public equity.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Arix Bioscience plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£1.61 |
| 52 Week High | UK£1.67 |
| 52 Week Low | UK£1.09 |
| Beta | 1.05 |
| 1 Month Change | 8.05% |
| 3 Month Change | 33.06% |
| 1 Year Change | 28.80% |
| 3 Year Change | -33.47% |
| 5 Year Change | -11.54% |
| Change since IPO | -32.47% |
Recent News & Updates
Recent updates
Shareholder Returns
| 3HY | DE Capital Markets | DE Market | |
|---|---|---|---|
| 7D | -3.6% | -0.7% | -1.7% |
| 1Y | 28.8% | 17.1% | -0.2% |
Return vs Industry: 3HY exceeded the German Capital Markets industry which returned 6.2% over the past year.
Return vs Market: 3HY exceeded the German Market which returned -1.4% over the past year.
Price Volatility
| 3HY volatility | |
|---|---|
| 3HY Average Weekly Movement | 5.9% |
| Capital Markets Industry Average Movement | 4.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 3HY has not had significant price volatility in the past 3 months.
Volatility Over Time: 3HY's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 9 | n/a | arixbioscience.com |
Arix Bioscience plc is a venture capital firm specializing in all stages of growth, seed stage, preclinical and clinical stage assets, startup, early stage, mid venture, late stage, growth capital investments as well as private and public equity. The firm seeks to invest in biotech companies, novel therapeutics, innovative technologies, medical innovation comprising healthcare and life sciences. It seeks to invest globally.
Arix Bioscience plc Fundamentals Summary
| 3HY fundamental statistics | |
|---|---|
| Market cap | €206.79m |
| Earnings (TTM) | €17.52m |
| Revenue (TTM) | €16.59m |
11.8x
P/E Ratio12.5x
P/S RatioIs 3HY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 3HY income statement (TTM) | |
|---|---|
| Revenue | UK£14.16m |
| Cost of Revenue | UK£0 |
| Gross Profit | UK£14.16m |
| Other Expenses | -UK£799.00k |
| Earnings | UK£14.96m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.12 |
| Gross Margin | 100.00% |
| Net Profit Margin | 105.64% |
| Debt/Equity Ratio | 0% |
How did 3HY perform over the long term?
See historical performance and comparison